Table 2.
Ruxolitinib Naïve Control Cohort Therapies
| Myelofibrosis | N=57 |
|---|---|
| No pharmacological intervention | 26 (45.6%) |
| Hydroxyurea | 8 (14%) |
| Anagrelide | 3 (5.3%) |
| Danazol | 3 (5.3%) |
| Peginterferon alfa-2a | 3 (5.3%) |
| Darbepoetin alfa | 2 (3.5%) |
| Decitabine | 2 (3.5%) |
| LBH589 | 2 (3.5%) |
| Thalidomide | 2 (3.5%) |
| Busulfan | 1 (1.8%) |
| KB004 | 1 (1.8%) |
| Luspatercept | 1 (1.8%) |
| Melphalan | 1 (1.8%) |
| Pomalidomide | 1 (1.8%) |
| PRM-151 | 1 (1.8%) |
| Non-myelofibrosis | N=16 |
| Hydroxyurea | 10 (62.5%) |
| Peginterferon alpha-2a | 4 (25%) |
| Anagrelide | 2 (12.5%) |